NEW YORK (GenomeWeb) – Agilent Technologies announced today that it is extending a longstanding agreement with PerkinElmer to continue the supply of chips for Agilent's 2100 Bioanalyzer system.

The terms of the deal extension were not disclosed.

The 2100 Bioanalyzer, which was first introduced in 1999, is used in DNA sequencing, gene expression research, DNA fragment analysis, and quality control for protein-based drugs, among other applications, according to Agilent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.